SAN DIEGO, May 20, 2014 (BUSINESS WIRE) -- Gilead Sciences, Inc. GILD +0.65% today announced results from a placebo-controlled, Phase 2a challenge study in healthy adult patients intranasally infected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback